The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Therapeutic options following failure to JAK inhibitors
Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, reflects on therapeutic approaches for patients with myelofibrosis (MF) who have progressed on Janus kinase (JAK) inhibitors. Following progression on ruxolitinib, next-generation JAK inhibitors such as fedratinib may improve outcomes, as well as combination approaches with other targeted therapies, such as selinexor. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
